THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of ...
Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...
The public offering is expected to close on or about February 2, 2026, subject to the satisfaction of customary closing conditions. In addition, Lexicon has granted the underwriters a 30-day option to ...
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon ”) today announced that it has commenced an underwritten public offering to offer and ...
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...
Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...
There is a lot of enterprise data trapped in PDF documents. To be sure, gen AI tools have been able to ingest and analyze PDFs, but accuracy, time and cost have been less than ideal. New technology ...
State officials Hugh McDonald and Mike Rogers join Lexicon in honoring 40 employees as they graduate from the company’s unique workforce development initiative LITTLE ROCK – Lexicon, Inc., recognized ...
The construction industry is ranked among professions as one of the highest for suicides, with a suicide rate four times higher than the national average. As a male-dominated industry, mental health ...
A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. The timeline for the company to begin receiving payments is dependent on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results